Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 3, Issue 2
  5. Article
Volume 3, Issue 2
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Allergic rhinitis (AR) is a common chronic health problem in the United Arab Emirates (UAE). Achieving adequate symptom control is pivotal to successful AR management, which may be attained following a stepwise treatment algorithm. Despite the availability of several guideline recommendations for the best management of AR, morbidity remains high in patients with AR, with treatment goals being far from reach.

Objective

The objective of this consensus statement was to discuss the currently available knowledge on the treatment of AR and to provide an expert opinion on the use of MP-AzeFlu (azelastine HCl, AZE; 137 µg per spray) and INCS (fluticasone propionate, FP; 50 µg per spray) for the effective management of AR in the UAE.

Methods

A consensus meet involving 13 otorhinolaryngologists and one pulmonologist was held in Dubai, UAE, to discuss the current understanding of the treatment and management of AR.

Results

The panel advised to start AR pharmacotherapy with antihistamines (AH), leukotriene receptor antagonist (LTRA), INCS or MP-AzeFlu based on the visual analogue scale (VAS) score. In mild intermittent AR (VAS score <5/10), AH or LTRA is recommended as first-line therapy. However, in case of VAS score ≥5/10 or persistent AR, and treatment failure with AHs alone, INCS or MP-AzeFlu is recommended, followed by reassessment for 7 days to confirm a step-up or step-down therapy. Patients non-responsive to therapy were advised to step-up with MP-AzeFlu.

Conclusion

The panel advocated a combination of intranasal second-generation AH and INCS in a single device (Dymista®) as first-line therapy for the management of AR. The algorithm provided herein can be applied in most healthcare settings by following a step-up or step-down strategy based on the VAS scores for AR control in the UAE.

© 2022 Bentham Science Publishers
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/03666220913105943
2022-09-01
2025-01-20

  • From This Site

    /content/journals/nemj/10.2174/03666220913105943
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/3/2/NEMJ-3-2-11.html?itemId=/content/journals/nemj/10.2174/03666220913105943&mimeType=html&fmt=ahah

References

  1. BaiardiniI. BraidoF. BoniniM. CompalatiE. CanonicaG.W. Why do doctors and patients not follow guidelines?Curr. Opin. Allergy Clin. Immunol.20099322823310.1097/ACI.0b013e32832b465119390434
     [Google Scholar]
  2. BousquetJ. KhaltaevN. CruzA.A. DenburgJ. FokkensW.J. TogiasA. ZuberbierT. Baena-CagnaniC.E. CanonicaG.W. van WeelC. AgacheI. Aït-KhaledN. BachertC. BlaissM.S. BoniniS. BouletL.P. BousquetP.J. CamargosP. CarlsenK.H. ChenY. CustovicA. DahlR. DemolyP. DouaguiH. DurhamS.R. van WijkR.G. KalayciO. KalinerM.A. KimY.Y. KowalskiM.L. KunaP. LeL.T.T. LemiereC. LiJ. LockeyR.F. Mavale-ManuelS. MeltzerE.O. MohammadY. MullolJ. NaclerioR. O’HehirR.E. OhtaK. OuedraogoS. PalkonenS. PapadopoulosN. PassalacquaG. PawankarR. PopovT.A. RabeK.F. Rosado-PintoJ. ScaddingG.K. SimonsF.E.R. ToskalaE. ValovirtaE. van CauwenbergeP. WangD.Y. WickmanM. YawnB.P. YorganciogluA. YusufO.M. ZarH. Annesi-MaesanoI. BatemanE.D. Ben KhederA. BoakyeD.A. BouchardJ. BurneyP. BusseW.W. Chan-YeungM. ChavannesN.H. ChuchalinA. DolenW.K. EmuzyteR. GrouseL. HumbertM. JacksonC. JohnstonS.L. KeithP.K. KempJ.P. KlossekJ.M. Larenas-LinnemannD. LipworthB. MaloJ.L. MarshallG.D. NaspitzC. NekamK. NiggemannB. Nizankowska-MogilnickaE. OkamotoY. OrruM.P. PotterP. PriceD. StoloffS.W. VandenplasO. ViegiG. WilliamsD. World Health OrganizationGA(2)LEN AllerGen Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).Allergy200863Suppl. 86816010.1111/j.1398‑9995.2007.01620.x18331513
     [Google Scholar]
  3. StormsW. MeltzerE. NathanR. SeinerJ. Allergic rhinitis: The patient’s perspective.J. Allergy Clin. Immunol.1997996S825S82810.1016/S0091‑6749(97)80043‑7
     [Google Scholar]
  4. MarpleB.F. FornadleyJ.A. PatelA.A. FinemanS.M. FromerL. KrouseJ.H. LanierB.Q. PennaP. American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction.Otolaryngol. Head Neck Surg.20071366_supplSuppl.S107S12410.1016/j.otohns.2007.02.03117512862
     [Google Scholar]
  5. CiprandiG. IncorvaiaC. ScuratiS. PuccinelliP. SoffiaS. FratiF. RossiO. Patient-related factors in rhinitis and asthma: The satisfaction with allergy treatment survey.Curr. Med. Res. Opin.20112751005101110.1185/03007995.2011.55958021401446
     [Google Scholar]
  6. AbdulrahmanH. HadiU. TarrafH. GharagozlouM. KamelM. SolimanA. HamadW.A. HannaK.M. MostafaB.E. OmraniM. AbdelmotalA. MoukarzelN. Nasal allergies in the middle eastern population: Results from the “Allergies in Middle East survey”.Am. J. Rhinol. Allergy2012266_supplSuppl. 1S3S2310.2500/ajra.2012.26.383623232281
     [Google Scholar]
  7. BousquetJ. SchünemannH.J. TogiasA. BachertC. ErholaM. HellingsP.W. KlimekL. PfaarO. WallaceD. AnsoteguiI. AgacheI. BedbrookA. BergmannK.C. BewickM. BonniaudP. Bosnic-AnticevichS. BosséI. BouchardJ. BouletL.P. BrozekJ. BrusselleG. CalderonM.A. CanonicaW.G. CaraballoL. CardonaV. CasaleT. CecchiL. ChuD.K. CostaE.M. CruzA.A. CzarlewskiW. D’AmatoG. DevillierP. DykewiczM. EbisawaM. FauquertJ.L. FokkensW.J. FonsecaJ.A. FontaineJ.F. GemiciogluB. van WijkR.G. HaahtelaT. HalkenS. IerodiakonouD. IinumaT. IvancevichJ.C. JutelM. KaidashevI. KhaitovM. KalayciO. Kleine TebbeJ. KowalskiM.L. KunaP. KvedarieneV. La GruttaS. Larenas-LinnemannD. LauS. LauneD. LeL. LiebermanP. Lodrup CarlsenK.C. LourençoO. MarienG. Carreiro-MartinsP. MelénE. MendittoE. NeffenH. MercierG. MosguesR. MullolJ. MuraroA. NamazovaL. NovellinoE. O’HehirR. OkamotoY. OhtaK. ParkH.S. PanznerP. PassalacquaG. Pham-ThiN. PriceD. RobertsG. RocheN. RollandC. RosarioN. RyanD. SamolinskiB. Sanchez-BorgesM. ScaddingG.K. ShamjiM.H. SheikhA. BomA.M.T. Toppila-SalmiS. TsiligianniI. Valentin-RostanM. ValiulisA. ValovirtaE. VenturaM.T. WalkerS. WasermanS. YorganciogluA. ZuberbierT. Allergic Rhinitis and Its Impact on Asthma Working Group Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence.J. Allergy Clin. Immunol.202014517080.e310.1016/j.jaci.2019.06.04931627910
     [Google Scholar]
  8. BrożekJ.L. BousquetJ. AgacheI. AgarwalA. BachertC. Bosnic-AnticevichS. Brignardello-PetersenR. CanonicaG.W. CasaleT. ChavannesN.H. Correia de SousaJ. CruzA.A. Cuello-GarciaC.A. DemolyP. DykewiczM. Etxeandia-IkobaltzetaI. FlorezI.D. FokkensW. FonsecaJ. HellingsP.W. KlimekL. KowalskiS. KunaP. LaisaarK.T. Larenas-LinnemannD.E. Lødrup CarlsenK.C. ManningP.J. MeltzerE. MullolJ. MuraroA. O’HehirR. OhtaK. PanznerP. PapadopoulosN. ParkH.S. PassalacquaG. PawankarR. PriceD. RivaJ.J. RoldánY. RyanD. SadeghiradB. SamolinskiB. Schmid-GrendelmeierP. SheikhA. TogiasA. ValeroA. ValiulisA. ValovirtaE. VentrescaM. WallaceD. WasermanS. WickmanM. WierciochW. Yepes-NuñezJ.J. ZhangL. ZhangY. ZidarnM. ZuberbierT. SchünemannH.J. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision.J. Allergy Clin. Immunol.2017140495095810.1016/j.jaci.2017.03.05028602936
     [Google Scholar]
  9. AlsowaidiS. AbdulleA. ShehabA. ZuberbierT. BernsenR. Allergic rhinitis: Prevalence and possible risk factors in a Gulf Arab population.Allergy201065220821210.1111/j.1398‑9995.2009.02123.x19735489
     [Google Scholar]
  10. OwayedA. BehbehaniN. Al-MomenJ. Changing prevalence of asthma and allergic diseases among Kuwaiti children. An ISAAC Study (Phase III).Med. Princ. Pract.200817428428910.1159/00012960718523395
     [Google Scholar]
  11. JanahiI.A. BenerA. BushA. Prevalence of asthma among Qatari schoolchildren: International Study of Asthma and Allergies in Childhood, Qatar.Pediatr. Pulmonol.2006411808610.1002/ppul.2033116283628
     [Google Scholar]
  12. AlmehiziaA.A. AlEssaR.K. AlwusaidiK.M. AlzamilK.A. AlJumahM. AljohaniS. AlmutairiA.F. SalamM. Allergic rhinitis: Disease characteristics and coping measures in Saudi Arabia.PLoS One2019146e021718210.1371/journal.pone.021718231242201
     [Google Scholar]
  13. BlaissM.S. MeltzerE.O. DereberyM.J. BoyleJ.M. Patient and healthcare-provider perspectives on the burden of allergic rhinitis.Allergy Asthma Proc.2007283Suppl. 141010.2500/aap.2007.28.299118307838
     [Google Scholar]
  14. SheddenA. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: Findings from a large online survey.Treat. Respir. Med.20054643944610.2165/00151829‑200504060‑0000716336028
     [Google Scholar]
  15. LeynaertB. NeukirchC. LiardR. BousquetJ. NeukirchF. Quality of life in allergic rhinitis and asthma. A population-based study of young adults.Am. J. Respir. Crit. Care Med.200016241391139610.1164/ajrccm.162.4.991203311029350
     [Google Scholar]
  16. MeltzerE.O. NathanR. DereberyJ. StangP.E. CampbellU.B. YehW.S. CorraoM. StanfordR. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the Burden of Rhinitis in America survey.Allergy Asthma Proc.200930324425410.2500/aap.2009.30.323019549425
     [Google Scholar]
  17. SihT. MionO. Allergic rhinitis in the child and associated comorbidities.Pediatr. Allergy Immunol.2010211-Part-IIe107e11310.1111/j.1399‑3038.2009.00933.x
     [Google Scholar]
  18. StullD.E. RobertsL. FrankL. HeithoffK. Relationship of nasal congestion with sleep, mood, and productivity.Curr. Med. Res. Opin.200723481181910.1185/030079907X17879317407638
     [Google Scholar]
  19. YounaT. FinnL. KimH. Nasal Obstruction as a Risk Factor for Sleep-Disordered Breathing.Am. J. Rhinol.1997114332
     [Google Scholar]
  20. HorakF. ZieglmayerU.P. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis.Expert Rev. Clin. Immunol.20095665966910.1586/eci.09.3820477689
     [Google Scholar]
  21. EllisA.K. ZhuY. SteacyL.M. WalkerT. DayJ.H. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis.Allergy Asthma Clin. Immunol.2013911610.1186/1710‑1492‑9‑1623635091
     [Google Scholar]
  22. WilsonA.M. O’ByrneP.M. ParameswaranK. Leukotriene receptor antagonists for allergic rhinitis: A systematic review and meta-analysis.Am. J. Med.2004116533834410.1016/j.amjmed.2003.10.03014984820
     [Google Scholar]
  23. NishimuraM. KogaT. KamimuraT. SatoR. NatoriH. MatsuoK. AizawaH. Comparison of leukotriene receptor antagonists and anti-histamines as an add-on therapy in patients with asthma complicated by allergic rhinitis.Kurume Med. J.201158191410.2739/kurumemedj.58.922027192
     [Google Scholar]
  24. ErdoğanB. A. SanlıA. PaksoyM. AltınG. AydınS. Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination.J. ear, nose, throat2014244217224
     [Google Scholar]
  25. CingiC. OghanF. EskiizmirG. YazA. UralA. ErdogmusN. Desloratadine-montelukast combination improves quality of life and decreases nasal obstruction in patients with perennial allergic rhinitis.Int. Forum Allergy Rhinol.201331080180610.1002/alr.2118523733270
     [Google Scholar]
  26. PrennerB. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US.J. Asthma Allergy2016913514310.2147/JAA.S9817227468241
     [Google Scholar]
  27. DerendorfH. MunzelU. PetzoldU. MausJ. MascherH. HermannR. BousquetJ. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.Br. J. Clin. Pharmacol.201274112513310.1111/j.1365‑2125.2012.04222.x22356350
     [Google Scholar]
  28. CarrW. BernsteinJ. LiebermanP. MeltzerE. BachertC. PriceD. MunzelU. BousquetJ. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.J. Allergy Clin. Immunol.2012129512821289.e1010.1016/j.jaci.2012.01.07722418065
     [Google Scholar]
  29. BousquetJ. MeltzerE.O. CourouxP. KoltunA. KopietzF. MunzelU. KuhlH.C. NguyenD.T. SalapatekA.M. PriceD. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber.J. Allergy Clin. Immunol. Pract.20186517261732.e610.1016/j.jaip.2018.01.03129425904
     [Google Scholar]
  30. MeltzerE.O. WallaceD. DykewiczM. ShneyerL. Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds?J. Allergy Clin. Immunol. Pract.201644682688.e610.1016/j.jaip.2016.02.00627084419
     [Google Scholar]
  31. MeltzerE.O. LaForceC. RatnerP. PriceD. GinsbergD. CarrW. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety.Allergy Asthma Proc.201233432433210.2500/aap.2012.33.358722856633
     [Google Scholar]
  32. KlimekL. BachertC. MösgesR. MunzelU. PriceD. VirchowJ.C. WahnU. BousquetJ. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study.Allergy Asthma Proc.2015361404710.2500/aap.2015.36.382325562555
     [Google Scholar]
  33. KlimekL. BachertC. StjärneP. DollnerR. LarsenP. HaahrP. AgacheI. ScaddingG. PriceD. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study.Allergy Asthma Proc.201637537638610.2500/aap.2016.37.397927657521
     [Google Scholar]
  34. KaulsayR. NguyenD.T. KuhlH.C. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy.Immun. Inflamm. Dis.20186445646410.1002/iid3.23730306729
     [Google Scholar]
  35. BousquetJ. DahlR. KhaltaevN. Global alliance against chronic respiratory diseases.Allergy200762321622310.1111/j.1398‑9995.2007.01307.x17298337
     [Google Scholar]
  36. KhaltaevN. GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership.J. Thorac. Dis.20179114676468910.21037/jtd.2017.11.9129268538
     [Google Scholar]
  37. BousquetJ. MohammadY. BedbrookA. ToT. McGihonR. BárbaraC. Melo-GomesE. Rosado-PintoJ. SimãoP. GeorgeF. PunturieriA. KileyJ.P. NunesE. CossaA. CamargosP. StelmachR. CruzA.A. RostanM.V. YañezA. González-DíazS.N. Urrutia-PereiraM. CalderonM.A. GómezR.M. GermanZ. KolekV. ŠpičákV. LanL.T.T. HurdS. LenfantC. YorganciogluA. GemicioğluB. EkinciB. OzkanZ. Abou Al-ZahabB. DmeiriehA. ShifaR. FarounH. AlJaberA. HalloumR. FatmehY. AlzeinA. AloushJ. DibG. ShaabanR. ArraisM. do Céu TeixeiraM. ConceiçãoC. FerrinhoP. Country activities of Global Alliance against Chronic Respiratory Diseases (GARD): Focus presentations at the 11th GARD General Meeting, Brussels.J. Thorac. Dis.201810127064707210.21037/jtd.2018.12.8430746253
     [Google Scholar]
  38. BousquetJ. CaimmiD.P. BedbrookA. BewickM. HellingsP.W. DevillierP. ArnavielheS. BachertC. BergmannK.C. CanonicaG.W. ChavannesN.H. CruzA.A. DahlR. DemolyP. De VriesG. Mathieu-DupasE. FinkwagnerA. FonsecaJ. GuldemondN. HaahtelaT. Hellqvist-DahlB. JustJ. KeilT. KlimekL. KowalskiM.L. KuitunenM. KunaP. KvedarieneV. LauneD. PereiraA.M. Carreiro-MartinsP. MelénE. Morais-AlmeidaM. MullolJ. MuraroA. MurrayR. Nogueira-SilvaL. PapadopoulosN.G. PassalacquaG. PortejoieF. PriceD. RyanD. SamolinskiB. SheikhA. SirouxV. SprangerO. Todo BomA. TomazicP.V. ValeroA. ValovirtaE. ValiulisA. VandenPlasO. van der MeulenS. van EerdM. WickmanM. ZuberbierT. Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study.Allergy201772685786510.1111/all.1312528072463
     [Google Scholar]
  39. BédardA. BasagañaX. AntoJ.M. Garcia-AymerichJ. DevillierP. ArnavielheS. BedbrookA. OnoratoG.L. CzarlewskiW. MurrayR. AlmeidaR. FonsecaJ. CostaE. MalvaJ. Morais-AlmeidaM. PereiraA.M. Todo-BomA. MendittoE. StellatoC. VenturaM.T. CruzA.A. StelmachR. da SilvaJ. Larenas-LinnemannD. Fuentes-PérezJ.M. Huerta-VillalobosY.R. EmuzyteR. KvedarieneV. ValiulisA. KunaP. SamolinskiB. KlimekL. MösgesR. PfaarO. ShamaiS. Annesi-MaesanoI. BosseI. DemolyP. FontaineJ.F. CardonaV. MullolJ. ValeroA. Roller-WirnsbergerR.E. TomazicP.V. ChavannesN.H. FokkensW.J. ReitsmaS. BewickM. RyanD. SheikhA. HaahtelaT. Toppila-SalmiS. ValovirtaE. MakrisM. PapadopoulosN.G. ProkopakisE.P. PsarrosF. CingiC. GemicioğluB. YorganciogluA. Bosnic-AnticevichS. O’HehirR.E. BachertC. HellingsP.W. PuginB. Bindslev-JensenC. EllerE. KullI. MelénE. WickmanM. De VriesG. van EerdM. AgacheI. AnsoteguiI.J. DykewiczM.S. CasaleT. WallaceD. WasermanS. LauneD. BousquetJ. MASK study group Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study.J. Allergy Clin. Immunol.20191441135143.e610.1016/j.jaci.2019.01.05330951790
     [Google Scholar]
  40. SchatzM. MeltzerE.O. NathanR. DereberyM.J. MintzM. StanfordR.H. DalalA.A. SilveyM.J. KosinskiM. Psychometric validation of the Rhinitis Control Assessment Test: A brief patient-completed instrument for evaluating rhinitis symptom control.Ann. Allergy Asthma Immunol.2010104211812410.1016/j.anai.2009.11.06320306814
     [Google Scholar]
  41. DemolyP. JankowskiR. ChassanyO. BessahY. AllaertF-A. Validation of a self-questionnaire for assessing the control of allergic rhinitis.Clin. Exp. Allergy201141686086810.1111/j.1365‑2222.2011.03734.x21518040
     [Google Scholar]
  42. DemolyP. BousquetP.J. MesbahK. BousquetJ. DevillierP. Visual analogue scale in patients treated for allergic rhinitis: An observational prospective study in primary care.Clin. Exp. Allergy201343888188810.1111/cea.1212123889242
     [Google Scholar]
  43. OhtaK. Jean BousquetP. AkiyamaK. AdachiM. IchinoseM. EbisawaM. TamuraG. NagaiA. NishimaS. FukudaT. MorikawaA. OkamotoY. KohnoY. SaitoH. TakenakaH. GrouseL. BousquetJ. The SACRA Study in Japan Visual analog scale as a predictor of GINA-defined asthma control. The SACRA study in Japan.J. Asthma201350551452110.3109/02770903.2013.78672623506422
     [Google Scholar]
  44. BousquetP.J. BachertC. CanonicaG.W. CasaleT.B. MullolJ. KlossekJ.M. ZuberbierT. BousquetJ. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: A cluster randomized trial.J. Allergy Clin. Immunol.20101263666668.e5, 510.1016/j.jaci.2010.06.03420816198
     [Google Scholar]
  45. LicariA. CastagnoliR. De FilippoM. FoiadelliT. ToscaM.A. MarsegliaG.L. CiprandiG. Current and emerging biologic therapies for allergic rhinitis and chronic rhinosinusitis.Expert Opin. Biol. Ther.202020660961910.1080/14712598.2020.172935032053391
     [Google Scholar]
  46. D’AddioA. RuizN. MayerM. MurrayR. BachertC. Deposition characteristics of a new allergic rhinitis nasal spray (MP29‐02*) in an anatomical model of the human nasal cavity.Clin. Transl. Allergy20155S44010.1186/2045‑7022‑5‑S4‑P40
     [Google Scholar]
  47. Roca-FerrerJ. PujolsL. Pérez-GonzálezM. AlobidI. CallejasB. Vicens-ArtésS. FuentesM. ValeroA. PicadoC. CastorD. NguyenD. MullolJ. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers.Allergy Asthma Clin. Immunol.20181418610.1186/s13223‑018‑0311‑430574167
     [Google Scholar]
  48. LipworthB. NewtonJ. RamB. SmallI. SchwarzeJ. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: A consensus statement from an expert panel.NPJ Prim. Care Respir. Med.2017271310.1038/s41533‑016‑0001‑y28115736
     [Google Scholar]
  49. KlimekL. BachertC. PfaarO. BeckerS. BieberT. BrehlerR. BuhlR. CasperI. ChakerA. CzechW. FischerJ. FuchsT. GerstlauerM. HörmannK. JakobT. JungK. KoppM.V. MahlerV. MerkH. MülleneisenN. NematK. RabeU. RingJ. SalogaJ. SchlenterW. Schmidt-WeberC. SeyfarthH. SperlA. SpindlerT. StaubachP. StriethS. TreudlerR. VogelbergC. WallrafenA. WehrmannW. WredeH. ZuberbierT. BedbrookA. CanonicaG.W. CardonaV. CasaleT.B. CzarlewskiW. FokkensW.J. HamelmannE. HellingsP.W. JutelM. Larenas-LinnemannD. MullolJ. PapadopoulosN.G. SalmiS.T. WerfelT. BousquetJ. ARIA guideline 2019: Treatment of allergic rhinitis in the German health system.Allergol. Select201931225010.5414/ALX02120E32176226
     [Google Scholar]
  50. WallaceD.V. DykewiczM.S. OppenheimerJ. PortnoyJ.M. LangD.M. Pharmacologic treatment of seasonal allergic rhinitis: Synopsis of guidance from the 2017 joint task force on practice parameters.Ann. Intern. Med.20171671287688110.7326/M17‑220329181536
     [Google Scholar]
  51. ScaddingG.K. DurhamS.R. MirakianR. JonesN.S. LeechS.C. FarooqueS. RyanD. WalkerS.M. ClarkA.T. DixonT.A. JollesS.R.A. SiddiqueN. CullinanP. HowarthP.H. NasserS.M. British Society for Allergy and Clinical Immunology BSACI guidelines for the management of allergic and non-allergic rhinitis.Clin. Exp. Allergy2008381194210.1111/j.1365‑2222.2007.02888.x18081563
     [Google Scholar]
  52. PatelP. D’AndreaC. SacksH.J. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber.Am. J. Rhinol.200721449950310.2500/ajr.2007.21.305817882923
     [Google Scholar]
  53. PatelP. RolandP.S. MarpleB.F. BenningerP.J. MargaliasH. BrubakerM. DrakeM. PottsS.L. WallG.M. WallG.M. An assessment of the onset and duration of action of olopatadine nasal spray.Otolaryngol. Head Neck Surg.2007137691892410.1016/j.otohns.2007.08.00518036421
     [Google Scholar]
  54. SalapatekA.M. LeeJ. PatelD. D’AngeloP. LiuJ. ZimmererR.O.Jr PipkinJ.D. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis.Allergy Asthma Proc.201132322122910.2500/aap.2011.32.344421477425
     [Google Scholar]
  55. HorakF. Petra ZieglmayerU. ZieglmayerR. KavinaA. MarschallK. MunzelU. PetzoldU. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: A pharmacodynamic study of onset of action and efficacy.Curr. Med. Res. Opin.200622115115710.1185/030079906X8030516393441
     [Google Scholar]
  56. MurdochR.D. BareilleP. IgnarD. MillerS.R. GuptaA. BoardleyR. ZieglmayerP. ZieglmayerR. LemelP. HorakF. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis.Clin. Exp. Allergy20154581346135510.1111/cea.1255625900517
     [Google Scholar]
  57. ZieglmayerP. ZieglmayerR. BareilleP. RousellV. SalmonE. HorakF. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber.Curr. Med. Res. Opin.20082461833184010.1185/0300799080215579218498678
     [Google Scholar]
/content/journals/nemj/10.2174/03666220913105943
Loading
An Algorithm Recommendation for Management of Allergic Rhinitis in the United Arab Emirates: A Consensus Statement from an Expert Panel
NEW Emirates Medical J 3, e130922208760 (2022); https://doi.org/10.2174/03666220913105943
/content/journals/nemj/10.2174/03666220913105943
/content/journals/nemj/10.2174/03666220913105943
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Allergic rhinitis; Azelastine HCl; Chronic health problem; Dymista; Fluticasone propionate; Treatment algorithm

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test